Profile data is unavailable for this security.
About the company
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
- Revenue in USD (TTM)9.76m
- Net income in USD-41.30m
- Incorporated2013
- Employees49.00
- LocationJaguar Health Inc200 PINE STREET SUITE 400SAN FRANCISCO 94104United StatesUSA
- Phone+1 (415) 371-8300
- Fax+1 (302) 655-5049
- Websitehttps://jaguar.health/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chimerix Inc | 41.00k | -82.59m | 85.41m | 72.00 | -- | 0.4906 | -- | 2,083.13 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
MDxHealth SA - ADR | -100.00bn | -100.00bn | 85.68m | 258.00 | -- | 11.89 | -- | -- | -- | -- | -- | 0.2641 | -- | -- | -- | -- | -- | -51.62 | -- | -64.72 | -- | 50.90 | -- | -117.64 | 1.81 | -- | 0.8513 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
BioXcel Therapeutics Inc | 1.38m | -179.05m | 85.93m | 74.00 | -- | -- | -- | 62.27 | -6.16 | -6.16 | 0.0474 | -1.89 | 0.0099 | 0.6343 | 8.65 | 18,648.65 | -128.10 | -74.57 | -163.23 | -84.06 | 8.62 | -- | -12,974.86 | -32,300.74 | 2.57 | -21.87 | 2.28 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
Beyondspring Inc | 1.75m | -21.03m | 87.58m | 35.00 | -- | -- | -- | 50.02 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 87.61m | 81.00 | -- | 0.905 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
Jaguar Health Inc | 9.76m | -41.30m | 87.84m | 49.00 | -- | 4.71 | -- | 9.00 | -3.64 | -3.64 | 0.4239 | 0.0676 | 0.1988 | 0.2513 | 5.08 | 199,204.10 | -85.33 | -95.29 | -153.34 | -163.54 | 79.13 | 67.28 | -429.27 | -522.28 | 1.34 | -2.95 | 0.8799 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
Spero Therapeutics Inc | 103.78m | 22.81m | 87.85m | 46.00 | 4.02 | 0.8082 | 3.79 | 0.8465 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
CEL-SCI Corp | 0.00 | -31.05m | 87.99m | 43.00 | -- | 6.44 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -39.26m | 89.34m | 10.00 | -- | 15.62 | -- | -- | -1.66 | -1.66 | 0.00 | 0.2048 | 0.00 | -- | -- | -- | -184.22 | -- | -404.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 89.82m | 47.00 | -- | 3.37 | -- | 89.82 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
Armata Pharmaceuticals Inc | 4.53m | -69.05m | 90.01m | 66.00 | -- | -- | -- | 19.87 | -1.91 | -1.91 | 0.1255 | -0.8877 | 0.0466 | -- | -- | 68,621.21 | -71.11 | -59.78 | -90.34 | -72.70 | -- | -- | -1,524.51 | -1,113.72 | -- | -1.68 | 1.64 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
Allovir Inc | 0.00 | -190.42m | 91.70m | 112.00 | -- | -- | -- | -- | -1.83 | -1.83 | 0.00 | -- | -- | -- | -- | 0.00 | -- | -52.85 | -- | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | -- | -- | -- | -- | -12.87 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Citadel Securities LLCas of 31 Dec 2023 | 193.33k | 0.09% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 192.34k | 0.09% |
JPMorgan Securities LLC (Investment Management)as of 31 Dec 2023 | 163.67k | 0.08% |
Geode Capital Management LLCas of 31 Dec 2023 | 129.42k | 0.06% |
Virtu Americas LLCas of 31 Dec 2023 | 100.68k | 0.05% |
Csenge Advisory Group LLCas of 31 Dec 2023 | 77.50k | 0.04% |
Two Sigma Securities LLCas of 31 Dec 2023 | 62.26k | 0.03% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 51.16k | 0.03% |
Boothbay Fund Management LLCas of 31 Dec 2023 | 49.77k | 0.02% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 46.38k | 0.02% |